PMID- 38046148
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231205
IS  - 2405-8440 (Print)
IS  - 2405-8440 (Electronic)
IS  - 2405-8440 (Linking)
VI  - 9
IP  - 12
DP  - 2023 Dec
TI  - Factors associated with rapid progression in fibrotic interstitial lung disease.
PG  - e22565
LID - 10.1016/j.heliyon.2023.e22565 [doi]
LID - e22565
AB  - BACKGROUND: Early identification of fibrotic interstitial lung disease (F-ILD) 
      patients with high risk of progression will help initiate early therapeutic 
      intervention and potential improvement of outcomes. This study was designed to 
      assess the predictors of progression in patients with F-ILD. METHODS: Patients 
      with F-ILD in Shanghai Pulmonary Hospital between January 1, 2019 and July 31, 
      2021 were retrospectively analyzed. The patients enrolled were divided into 
      progressive group and non-progressive group according to the specified criteria. 
      Baseline characteristics were collected and a multivariate regression was 
      conducted to identify independent predictors of progression. RESULTS: Of the 
      177 F-ILD cases, 87 were enrolled in the progressive group and 90 were in the 
      non-progressive group. The cohort included 11 types of F-ILD, primarily were 
      connective tissue disease-associated interstitial lung disease (CTD-ILD) (43, 
      24.3 %), idiopathic pulmonary fibrosis (IPF) (39, 22.0 %), interstitial pneumonia 
      with autoimmune features (IPAF) (32, 18.1 %), and unclassifiable (23, 13.0 %). 
      The highest proportion of progression was seen in nonspecific interstitial 
      pneumonia (NSIP) subgroup (66.7 %), followed by IPF (59.0 %) and HP (57.1 %). 
      After adjusting for gender and age, a course of disease longer than 9.5 months 
      (OR: 2.633; 95 % CI: 1.190-5.826, P = 0.017), lymphocyte in peripheral blood more 
      than 2.24 (10(9)/L) (OR: 2.670; 95 % CI: 1.095-6.510, P = 0.031), and emphysema 
      in high-resolution computed tomography (HRCT) (OR: 2.387; 95 % CI: 1.017-5.640, 
      P = 0.046) were independent predictors of progression in F-ILD patients. 
      CONCLUSIONS: This study suggested that in patients with F-ILD, long course of 
      disease, elevated blood lymphocyte and emphysema on HRCT were independent 
      predictors of progression, which may suggest utility in early therapeutic 
      intervention.
CI  - (c) 2023 Published by Elsevier Ltd.
FAU - Chen, Xianqiu
AU  - Chen X
AD  - Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji 
      University School of Medicine, Shanghai, China.
FAU - Ji, Qiuliang
AU  - Ji Q
AD  - Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji 
      University School of Medicine, Shanghai, China.
FAU - Yao, Qian
AU  - Yao Q
AD  - Department of Respiratory Medicine and Clinical Research Center, Shanghai 
      Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
FAU - Zhou, Ying
AU  - Zhou Y
AD  - Department of Respiratory Medicine and Clinical Research Center, Shanghai 
      Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
LA  - eng
PT  - Journal Article
DEP - 20231120
PL  - England
TA  - Heliyon
JT  - Heliyon
JID - 101672560
PMC - PMC10686856
OTO - NOTNLM
OT  - Course of disease
OT  - Emphysema
OT  - Fibrotic interstitial lung disease
OT  - Lymphocyte
OT  - Progression
COIS- The authors declare that they have no known competing financial interests or 
      personal relationships that could have appeared to influence the work reported in 
      this paper.
EDAT- 2023/12/04 06:42
MHDA- 2023/12/04 06:43
PMCR- 2023/11/20
CRDT- 2023/12/04 04:50
PHST- 2023/07/26 00:00 [received]
PHST- 2023/11/03 00:00 [revised]
PHST- 2023/11/15 00:00 [accepted]
PHST- 2023/12/04 06:43 [medline]
PHST- 2023/12/04 06:42 [pubmed]
PHST- 2023/12/04 04:50 [entrez]
PHST- 2023/11/20 00:00 [pmc-release]
AID - S2405-8440(23)09773-6 [pii]
AID - e22565 [pii]
AID - 10.1016/j.heliyon.2023.e22565 [doi]
PST - epublish
SO  - Heliyon. 2023 Nov 20;9(12):e22565. doi: 10.1016/j.heliyon.2023.e22565. 
      eCollection 2023 Dec.